KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCA Healthcare (HCA) Gains from Sales and Divestitures (2016 - 2025)

HCA Healthcare (HCA) has disclosed Gains from Sales and Divestitures for 11 consecutive years, with $717000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 59.51% to $717000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $717000.0, a 59.51% decrease, with the full-year FY2025 number at $717000.0, down 59.51% from a year prior.
  • Gains from Sales and Divestitures was $717000.0 for Q4 2025 at HCA Healthcare, down from $1.8 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.8 million in Q4 2021 to a low of $717000.0 in Q4 2025.
  • A 5-year average of $1.6 million and a median of $1.4 million in 2022 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: rose 27.14% in 2024, then plummeted 59.51% in 2025.
  • HCA Healthcare's Gains from Sales and Divestitures stood at $2.8 million in 2021, then plummeted by 49.38% to $1.4 million in 2022, then decreased by 0.43% to $1.4 million in 2023, then rose by 27.14% to $1.8 million in 2024, then tumbled by 59.51% to $717000.0 in 2025.
  • Per Business Quant, the three most recent readings for HCA's Gains from Sales and Divestitures are $717000.0 (Q4 2025), $1.8 million (Q4 2024), and $1.4 million (Q4 2023).